Does Tigecycline's Patent Protection Impact Its Cost?
Yes, tigecycline's patent protection directly influences its cost by enabling Wyeth (now Pfizer) to charge premium prices without generic competition. As the active ingredient in Tygacil, tigecycline faced no generic entry until patents began expiring, keeping U.S. list prices high—around $1,000-$2,000 per day of treatment during peak exclusivity.[1] Generic approval followed key patent losses, slashing costs by 80-90% in markets like India and later the U.S.
When Did Tigecycline's Key Patents Expire?
Tigecycline's main composition-of-matter patent (U.S. Patent 5,952,507) expired in 2015 after pediatric extensions. Formulation patents, like U.S. 7,858,661 for IV use, held until 2020, blocking ANDAs until then.[2] Check DrugPatentWatch.com for full details: Tygacil Patents.[3] Post-2020, generics from Sandoz and others entered, but some method-of-use patents linger until 2026-2031, limiting full competition.
How Much Have Generics Lowered Tigecycline Prices?
In the U.S., Tygacil's average wholesale price dropped from $1,800 per 50mg vial pre-generics to $200-400 post-2020 FDA approvals.[4] Internationally, generics sell for $50-100 per vial. Price impact varies by region: EU generics arrived earlier (2015), cutting costs faster than in patent-heavy markets like Japan.
What Happens If Patents Get Extended or Challenged?
Pfizer has pursued pediatric exclusivity and evergreening, adding 6 months to some expirations, which delayed generics and sustained high prices.[2] Challenges via Paragraph IV filings succeeded for most patents; unresolved ones (e.g., for specific infections) could block niche generics. No active litigation blocks broad entry as of 2023.
How Does Tigecycline Compare Cost-Wise to Alternatives?
| Drug | Monthly Cost (U.S., approx.) | Patent Status | Notes |
|------|------------------------------|---------------|-------|
| Tygacil (branded) | $50,000+ | Partial protection to 2031 | IV only, for MDR infections |
| Tigecycline generic | $10,000-20,000 | Available since 2020 | 80% cheaper than branded |
| Meropenem | $5,000-10,000 (generic) | Expired 2010s | Broader use, fewer resistances |
| Vancomycin | $2,000-5,000 (generic) | Long expired | Oral/IV, common alternative |
Generics make tigecycline competitive with these, but branded pricing remains elevated for hospitals.[5]
Why Do Hospitals Still Pay High Prices for Branded Tigecycline?
Shortages of generics (e.g., 2022-2023 recalls) and payer preferences for branded stability drive continued use of Tygacil at full price. Patents on delivery devices also add barriers.
Sources:
[1] IQVIA National Sales Perspectives (2022 pricing data).
[2] FDA Orange Book, tigecycline listings.
[3] DrugPatentWatch.com - Tygacil.
[4] CMS ASP Drug Pricing Files (2023).
[5] ASHP Drug Shortages Report (2023).